INKT — Mink Therapeutics Share Price
0.000.00%
Last trade - 00:00- $30.14m
- $30.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.13 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 5th, 2017
- Public Since
- October 15th, 2021
- No. of Shareholders
- 161
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,966,392
- Address
- 149 Fifth Avenue, Suite 500, NEW YORK, 10010
- Web
- https://www.minktherapeutics.com
- Phone
- +1 2129948250
- Auditors
- KPMG LLP
Upcoming Events for INKT
Mink Therapeutics Inc Annual Shareholders Meeting
Mink Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Mink Therapeutics Inc Earnings Release
Similar to INKT
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Mink Therapeutics share price?
As of Today at 22:04 UTC, shares in Mink Therapeutics are trading at $7.60. This share price information is delayed by 15 minutes.
How has the Mink Therapeutics share price performed this year?
Shares in Mink Therapeutics last closed at $7.60 and the price had moved by -21.6% over the past 365 days. In terms of relative price strength the Mink Therapeutics share price has underperformed the S&P500 Index by -29.31% over the past year.
What are the analyst and broker recommendations for Mink Therapeutics?
The overall consensus recommendation for Mink Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mink Therapeutics dividend yield?
Mink Therapeutics does not currently pay a dividend.
Does Mink Therapeutics pay a dividend?
Mink Therapeutics does not currently pay a dividend.
When does Mink Therapeutics next pay dividends?
Mink Therapeutics does not currently pay a dividend.
How do I buy Mink Therapeutics shares?
To buy shares in Mink Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mink Therapeutics?
As of the previous close price of $7.60, shares in Mink Therapeutics had a market capitalisation of $30.14m.
Where are Mink Therapeutics shares listed?
Here are the trading details for Mink Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INKT
What kind of share is Mink Therapeutics?
Based on an overall assessment of its quality, value and momentum Mink Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mink Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Mink Therapeutics is $48.33. That is 535.92% above the last closing price of $7.60.
Analysts covering Mink Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.63 for the next financial year.
Find out moreWhat is the trend in the Mink Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mink Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +7.68%.
As of the last closing price of $7.60, shares in Mink Therapeutics were trading -4.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mink Therapeutics PE Ratio?
The Mink Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mink Therapeutics?
We do not have data on Mink Therapeutics' directors